These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 20529786)
21. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Itzykson R; Fenaux P Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268 [TBL] [Abstract][Full Text] [Related]
22. [Myelodysplastic syndromes]. Geissler K Wien Med Wochenschr; 1991; 141(9-10):201-4. PubMed ID: 1949844 [TBL] [Abstract][Full Text] [Related]
23. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). List AF Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015 [TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Garcia-Manero G Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090 [TBL] [Abstract][Full Text] [Related]
26. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. Cazzola M Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660 [TBL] [Abstract][Full Text] [Related]
28. How to treat MDS without stem cell transplantation. Gattermann N Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S30-6. PubMed ID: 19857591 [TBL] [Abstract][Full Text] [Related]
29. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
30. Refractory anemia and the myelodysplastic syndromes. Lawrence LW Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893 [TBL] [Abstract][Full Text] [Related]
31. DNA methyltransferase inhibitors in myelodysplastic syndrome. Silverman LR Best Pract Res Clin Haematol; 2004 Dec; 17(4):585-94. PubMed ID: 15494296 [TBL] [Abstract][Full Text] [Related]
33. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures. Suwanawiboon B; Sumida KN Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897 [TBL] [Abstract][Full Text] [Related]
34. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications. Panani AD; Roussos C Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553 [TBL] [Abstract][Full Text] [Related]
35. Emerging drugs for the treatment of myelodysplastic syndrome. Nivatpumin PJ; Gore SD Expert Opin Emerg Drugs; 2005 Aug; 10(3):569-90. PubMed ID: 16083330 [TBL] [Abstract][Full Text] [Related]
36. The evolution of hematopoietic SCT in myelodysplastic syndrome. Kindwall-Keller T; Isola LM Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532 [TBL] [Abstract][Full Text] [Related]
38. Myelodysplasia: the good, the fair and the ugly. Schiffer CA Best Pract Res Clin Haematol; 2007 Mar; 20(1):49-55. PubMed ID: 17336254 [TBL] [Abstract][Full Text] [Related]
39. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes. Fenaux P; Ades L Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796 [TBL] [Abstract][Full Text] [Related]